Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Current perspectives on intracavernosal pharmacotherapy for erectile dysfunction


Thirty percent of males afflicted with erectile dysfunction (ED) do not respond to oral drugs, another 15% reveal contraindications to currently available therapy, and a subset of patients actually prefer injection therapy due to its predictable short time-to-onset of erection and reliable rigidity compared to oral drugs. This paper provides both a historical and current perspective on intracavernosal therapy and reviews the popular injectable therapeutic agents that are currently used for the treatment of ED. Emphasis is placed on the efficacy, mechanism of action and side effect profiles of approved and experimental injectable pharmacotherapy for ED.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Author information

Authors and Affiliations


Corresponding author

Correspondence to H Porst.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Porst, H. Current perspectives on intracavernosal pharmacotherapy for erectile dysfunction. Int J Impot Res 12 (Suppl 4), S91–S100 (2000).

Download citation

  • Published:

  • Issue Date:

  • DOI:


This article is cited by


Quick links